The study evaluated whether pre-existing RA was associated with a higher mortality and risk for immune-related adverse events with ICI use.
Joining Dr. Ishizawar in conducting this research were UNC colleagues; Dr. Amanda Lusa, Dr. Todd Schwartz, Carolina Alvarez, and Shruti Saxena Beem.
Learn more about the study findings via this summary in Rheumatology Advisor.